ERBB2 and breast cancer: Adjuvant chemotherapy (paclitaxel after doxorubicin and cyclophosphamide) with concurrent trastuzumab administrated to women after surgical resection of HER2-positive breast cancers had improved outcomes compared with adjuvant chemotherapy alone [198].